BREAST CANCER

Extending abemaciclib with endocrine therapy for 2 years continues to lower the risk of invasive disease and distant relapse in hormone receptor-positive, HER2-negative breast cancer, as demonstrated in the 5-year efficacy findings from the monarchE trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, Laura Huppert, MD, and participants discussed treatment approaches for a patient HR-positive, HER2-negative breast cancer with liver and lung metastases who continues to progress on endocrine therapy and CDK4/6 inhibitors.

In the first article of a 2-part series, Aditya Bardia, MD, MPH, explains how recent survival outcomes with sacituzumab govitecan impressed physicians treating patients with metastatic breast cancer.

Sandra M. Swain, MD, FACP, FASCO, reviews clinical trial data and how they inform the evolving treatment landscape in HER2+ early breast cancer.

Chirag Shah, MD, discusses the challenges in predicting the risk of local recurrence in patients with ductal carcinoma in situ, and what led to the DCISionRT test.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.

At a live virtual event, Jane Lowe Meisel, MD, provided insights into the latest practice updates for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Rebecca A. Shatsky, MD, looks to the future of biomarker testing in metastatic breast cancer and offers advice to community oncologists.

A medical oncologist discusses challenges with conducting molecular testing and reviews clinical trials focused on biomarkers for patients with ER+/HER2- metastatic breast cancer.

A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.

Rebecca A. Shatsky, MD, reviews biomarker testing guideline recommendations for patients with breast cancer and discusses testing practices upon progression.

An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.

A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.

Rebecca A. Shatsky, MD, provides an overview of ER+/HER2- metastatic breast cancer and discusses its incidence and prevalence.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.

IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues to be evaluated in a first-in-human, phase 1 study for patients with advanced solid tumors.

Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired resistance of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tiffany A. Traina, MD, reviewed data from the TROPiCS-02 and DESTINY-Breast04 and discussed using antibody-drug conjugates in patients with metastatic breast cancer.

Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.

In the second article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on the practice-changing use of sacituzumab govitecan and trastuzumab deruxtecan for patients with advanced breast cancer.

Key opinion leaders on breast cancer management share insight on the evolving role of antibody drug conjugates and their potential impact on care.

Following her review of TROPiCS-02, Joyce O’Shaughnessy, MD, shares data from the DESTINY-Breast04 study of T-DXd in HER2-low metastatic breast cancer.

Fertility preservation should be offered to anyone who is interested in becoming pregnant after chemotherapy for breast cancer.

Expert Joyce O’Shaughnessy, MD, reviews data from the TROPiCS-02 study of sacituzumab govitecan in HR+/HER2- metastatic breast cancer.

Expert perspectives on a second patient case of unmutated metastatic breast cancer and available treatment strategies in this setting.

Sara Tolaney, MD, MPH, discusses key takeaways from the TROPiCS-02 study of sacituzumab govitecan-hziy for patients with hormone receptor-positive/HER2-negative metastatic breast cancer, and highlights other trials evaluating the agent.

Expert panelists consider how they might apply data from the EMERALD study in their real-world management of HR+/HER2- metastatic breast cancer.

A focused review of data from the EMERALD study, which tested elacestrant, an oral SERD, in patients with HR+/HER2- metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Aditya Bardia, MD, MPH, discussed treatment approaches for a patient with hormone receptor–positive, HER2- negative metastatic breast cancer?

In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.